XT-Thrive bottle

DMSO-free,
Chemically Defined, Safe & Effective Cryopreservation Solution

XT-Thrive® is a DMSO-free, serum-free, protein-free, and chemically defined cryopreservation media for the preservation of mammalian cells at ultra-low temperatures (-70° C to -196° C). Designed and manufactured with the utmost quality in mind, XT-Thrive® is tailored to provide high cell recovery and functionality. It is a non-toxic & hyper-effective alternative to traditional cryopreservatives and is plug and play for cell & tissue manufacturing processes.

The Problem

Cryopreservation is a crucial part of manufacturing regenerative medicines.

Existing standards in cryopreservation use 5-10% dimethyl sulfoxide (DMSO) and often serum or serum albumin.

These products have not been significantly improved for over 50 years.

DMSO exhibits acute toxicity in patients and causes adverse cell mutations at low doses (0.1%).

Our Solution

XT-Thrive® enables non-toxic cryopreservation for life-saving regenerative medicines such as vaccines, cell & gene therapies, and engineered tissues.

patient mother and child

Benefits of XT-Thrive

DMSO-FREE AND NON-TOXIC

XT-Thrive® is a non-toxic and non-genotoxic cryopreservation solution that reduces the risks of adverse alterations in cellular phenotype during preservation and clinical side effects during and after cell therapy.

Chemically Defined

XT-Thrive® is a fully chemically defined formulation and contains no serum or recombinant proteins.

Uncompromised Performance

XT-Thrive® doesn‘t compromise on performance despite lacking DMSO. It is designed to preserve the viability, physical integrity, and ultimately the functionality of cells post-thaw after storage at -70° C or in liquid nitrogen.

Optimized Process For scale

XT-Thrive® enables a significant extension in the allowable timeframe for pre-freeze and post-thaw incubation. And unlike DMSO, no wash-out is required.

Plug and Play Integration

XT-Thrive® is extremely process-friendly and can be directly plugged into current workflows without requiring specialized instrumentation. It can directly replace the cryopreservation solutions that contains DMSO and/or serum.

Fields of Application of XT-Thrive®

XT-Thrive® has been validated by third parties in the following key therapeutic cells.

Cells icon

Cryopreservation Solution for Mammalian Cell Lines

HEK293, Jurkat, K562, TF-1, HL-1, HEPG-2, CHO, U2OS

Cells icon

Cryopreservation Solution for Mammalian Primary Cells

PBMCs, T Cells, CAR-T Cells, B Cells
iPSCs, iPSC-derived cardiomyocytes
BM and BM-derived HSCs and MSCs
Cord Blood and Cord blood-derived HSCs and MScs
Organoids

Skin tissue icon

Cryopreservation Solution for Tissues

Full-thickness skin grafts
Articular Cartilage

“XT-Thrive® reagents resulted in significantly improved viability of MSCs before freezing and post-thaw when the cells were kept at room temperature for hours, especially if the cells were cultured in serum-free media. This is a huge advantage in the manufacturing process, especially in the process of filling and transportation.”

– Steve Oh, PhD, Alan Lam, PhD, and Simon Cool, PhD
Agency for Science, Technology and Research, Singapore

XT-Thrive® Performance Tests

Resilience in an Intense Manufacturing and Uncontrolled Clinical Environment

It is generally recommended that the pre-freeze and post-thaw contact time for DMSO is limited to 30 seconds and 1-2 hours respectively; this ensures enhanced product quality. Prior to freezing, human mesenchymal stromal cells (MSCs) cultured in serum-free media in a monolayer format were exposed to different cryoprotectants. XT-Thrive® remained remarkably non-toxic, with a ~30% higher viability despite extended incubation times up to 24 hours when compared to Competitor C10. Demonstrating superior resilience post-thaw, previously frozen MSC monolayers were thawed and exposed to different cryoprotectants at room temperature for 2-6 hours. XT-Thrive® continued to remain remarkably non-toxic to MSC monolayers and maintained the ~30% higher viability despite incubation up to 6 hours while at room temperature compared to Competitor C10. 

High-Efficiency Nucleofection of Primary T Cells

In collaboration with a current customer, CD4/8 cells were isolated from leukopaks and cryopreserved in XT-Thrive®. After 7 days, cells were thawed, allowed to rest overnight, and activated. After culture, nucleofection was performed on day 11 and flow analysis on day 18. Preservation in XT-Thrive® ensured a 90% nucleofection efficiency compared to a 78% efficiency when preserved in a leading DMSO solution. On day 7 post-thaw nucleofection, cells preserved in XT-Thrive® retained a ~80% nucleofection efficiency compared to ~65% in DMSO.

Compatible with Large Scale Production Processes

Serum-free growth conditions are highly desirable in cGMP cell manufacturing but are often hindered by slower cell growth rates and other issues. MSCs were frozen for 1 week in LN2, and expanded in a serum-free solution. After thawing, cells were continuously cultured for 6 days. A 2.5-fold higher growth rate (purple) was seen at 6 days after freeze/thaw with XT-Thrive® in a serum-free 3D microcarrier culture compared to DMSO.

Preserved Cellular Function of Sensitive Cell Types

iPSC-derived cardiomyocytes often suffer from freezing injury with viability as low as 15% and take several days of culture to resume pacing. iPSC-derived cardiomyocytes stored in XT-Thrive® demonstrated not only high post-thaw viability (green, live cells), but also exhibited rapid recovery of original contractile function when compared to DMSO.

Preserve more of the ‘True Stem Cells’ for Bone Marrow Transplant

In collaboration with the Vitalant Research Institute, patient whole bone marrow was preserved with XT-Thrive® and field standard 10% DMSO plus 90% human serum albumin. The immediate post-thaw survival was comparable between both groups. On Day 3, the XT-Thrive® group shows >2X higher cell count for CD34+ and CD34+/CD133+ cells in comparison to the field standard solution. The in vivo transplant study can be found in the Nature subjournal, Bone Marrow Transplantation.